Holen Sie sich die Stockscreener-App
2.79
1.45%
0.04
Vorhandelsmarkt:
2.78
-0.01
-0.36%
Schlusskurs vom Vortag:
$2.75
Offen:
$2.71
24-Stunden-Volumen:
11,101
Relative Volume:
0.13
Marktkapitalisierung:
$3.81M
Einnahmen:
$35.75M
Nettoeinkommen (Verlust:
$11.57M
KGV:
-0.7329
EPS:
-3.8069
Netto-Cashflow:
$-26.25M
1W Leistung:
-6.69%
1M Leistung:
-22.50%
6M Leistung:
-67.67%
1J Leistung:
-78.94%
1-Tages-Spanne:
$2.65
$2.80
1-Wochen-Bereich:
$2.64
$3.10
52-Wochen-Spanne:
$2.47
$20.28
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Vergleichen Sie RDHL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
2.79 | 3.81M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
UTHR
United Therapeutics Corp
|
306.97 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-08-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-11 | Eingeleitet | BTIG Research | Buy |
| 2019-07-12 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | Eingeleitet | Nomura | Buy |
| 2017-10-06 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-10-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-24 | Bestätigt | FBR & Co. | Outperform |
| 2016-07-27 | Bestätigt | FBR Capital | Outperform |
| 2015-09-29 | Eingeleitet | Nomura | Buy |
| 2015-07-29 | Bestätigt | ROTH Capital | Buy |
| 2015-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-15 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Redhill Biopharma Ltd Adr Aktie (RDHL) Neueste Nachrichten
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance
Cathie Wood Predictions 2022 - New Trader U
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib - Yahoo Finance
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement - Yahoo Finance
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
RedHill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Redhill Biopharma Ltd Adr-Aktie (RDHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):